

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA HEALTH

China Health Technology Group Holding Company Limited

中國健康科技集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1069)

(1) RESIGNATION OF EXECUTIVE DIRECTOR (2) CHANGE IN CHIEF EXECUTIVE OFFICER (3) CHANGE IN COMPOSITION OF NOMINATION COMMITTEE

RESIGNATION OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of China Health Technology Group Holding Company Limited (the “**Company**”) hereby announces that Mr. Wang Yibin (“**Mr. Wang**”) has resigned as an executive Director with effect from 1 December 2025 due to his other business engagements requiring more of time.

Mr. Wang has confirmed that there is no disagreement with the Board and that he is not aware of any matters that need to be brought to the attention of the shareholders of the Company or the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in relation to his resignation. The Board takes this opportunity to express its sincere gratitude to Mr. Wang for his invaluable contributions to the Company in the past.

CHANGE IN CHIEF EXECUTIVE OFFICER

Following the resignation of Mr. Wang as an executive Director, the Board announces that Mr. Wang has resigned as the chief executive officer of the Company (the “**Chief Executive Officer**”) with effect from 1 December 2025.

Mr. Wang has confirmed that he has no disagreement with the Board and that he is not aware of any matters that need to be brought to the attention of the Shareholders or the Stock Exchange in relation to his resignation as the Chief Executive Officer. The Board would like to express its gratitude to Mr. Wang for his significant contribution during his term of office as the Chief Executive Officer.

The Board is pleased to announce that Ms. Bu Xue (“**Ms. Bu**”) has been appointed as the Chief Executive Officer with effect from 1 December 2025.

The biography of Ms. Bu is as follows:

Ms. Bu, aged 36, was appointed as an independent non-executive Director on 14 August 2023 and was re-designated as an executive Director on 1 April 2025. Ms. Bu obtained her Bachelor’s degree in Business Administration from Zhengzhou University of Aeronautics in July 2011. She has attained the accounting professional qualification issued by Ministry of Human Resources and Social Security and Ministry of Finance of the People’s Republic of China since September 2020 and has attained the qualification of tax advisor issued by The China Certified Tax Agents Association since December 2022. She has over ten years of experience in marketing and business development.

Save as disclosed above, as at the date of this announcement, Ms. Bu (i) does not hold any other position with the Company or other members of the Group; (ii) does not have any relationship with the Directors, senior management, substantial or controlling shareholders (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)) of the Company; (iii) has not held any directorship in any other public companies in the last three years, the securities of which are listed on any securities market in Hong Kong or overseas or other major appointments and professional qualifications; and (iv) does not have any interests in the shares, underlying shares and debentures of the Company which are required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Mr. Bu has entered into a contract of appointment as an executive Director with the Company for a term of one year with effect from 1 April 2025, subject to retirement and re-election at general meetings pursuant to the articles of association of the Company. As at the date of this announcement, the Company and Ms. Bu has entered into a supplemental contract of appointment to supplement certain information including but not limited to the appointment of Ms. Bu as the Chief Executive Officer. Ms. Bu is entitled to receive a total annual remuneration of HK\$96,000 for her roles as an executive Director and the Chief Executive Officer. The remuneration is recommended by the remuneration committee of the Board with reference to the remuneration policy of the Company, her duties and the prevailing market level of remuneration for executives of similar positions.

Save as disclosed above, there is no other information which is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Ms. Bu as the Chief Executive Officer that need to be brought to the attention of the Shareholders and the Stock Exchange in relation to her appointment.

CHANGE IN COMPOSITION OF NOMINATION COMMITTEE

Following the resignation of Mr. Wang, he has ceased to be a member of the nomination committee of the Board (the “**Nomination Committee**”) with effect from 1 December 2025. Mr. Chau Wing Nam, an independent non-executive Director, has been appointed as a member of the Nomination Committee with effect from 1 December 2025.

By Order of the Board
China Health Technology Group Holding Company Limited
Professor Fei Phillip
Chairman and Executive Director

Hong Kong, 1 December 2025

As at the date of this announcement, the Board comprises Professor Fei Phillip and Ms. Bu Xue as executive Directors; and Mr. Guo Zhonglong, Mr. Chau Wing Nam and Ms. Liu Shuhua as independent non-executive Directors.